V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310008420 | 310005593 | 1.58 | 71.35 | Curative (C) | 2016-04-17 | 2016-04-28 | CETUXIMAB | N | N | 310022562 | METHOTREXATE |
| 310008421 | 310005594 | 1.74 | null | Adjuvant (A) | 2014-02-18 | 2014-04-30 | CTD | N | N | 310022639 | HYDROXYCARBAMIDE |
| 310008422 | 310005596 | null | 47.6 | Palliative (P) | 2015-01-13 | 2015-01-13 | Temozolomide 200mg/m2 | 2 | N | 310022679 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 310008423 | 310005596 | 1.69 | 80.7 | Palliative (P) | 2015-08-02 | 2015-08-15 | Lenalidomide Cycle 26 onwards (PAS) | 02 | N | 310022679 | METHOTREXATE HIGH DOSE |
| 310008424 | 310008486 | 1.76 | 59.2 | Adjuvant (A) | 2015-08-08 | 2015-08-09 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | null | N | 310022751 | GEMCITABINE + OXALIPLATIN |
| 310008425 | 310005598 | 1.8 | 0 | Curative (C) | 2014-06-23 | 2014-07-05 | CETUXIMAB | N | N | 310022751 | VISMODEGIB |
| 310008426 | 310005600 | 0 | 14.3 | Curative (C) | 2017-03-08 | 2017-03-10 | SPIRE Trial | N | N | 310022786 | IVE-R |
| 310008427 | 310005601 | 1.5 | 59.3 | Palliative (P) | 2019-03-31 | 2019-04-04 | Methotrexate High Dose (3g/m2) | 02 | N | 310022819 | IMATINIB |
| 310008428 | 310005603 | 1.65 | null | Palliative (P) | 2017-01-09 | 2017-01-23 | ECF | N | N | 310022826 | VEMURAFENIB |
| 310008429 | 310005604 | 1.64 | 73.5 | Palliative (P) | 2016-05-21 | 2016-05-23 | Eribulin | 02 | N | 310022843 | TOPOTECAN |
| 310008430 | 310005604 | 1.52 | 64 | Palliative (P) | 2018-10-12 | 2018-10-19 | Oxaliplatin + Modified de Gramont | Y | N | 310022843 | ICON8B TRIAL |
| 310008431 | 310005604 | null | 66 | Palliative (P) | 2016-06-12 | 2016-06-18 | Fludarabine + Melphalan RIC Allo | N | N | 310022843 | CAPECITABINE |
| 310008432 | 310010866 | 1.6 | null | Palliative (P) | 2018-08-28 | 2018-09-02 | Gemcitabine + Oxaliplatin | N | N | 310022924 | ATEZOLIZUMAB |
| 310008433 | 310005608 | 1.55 | 67 | Adjuvant (A) | 2016-08-27 | 2016-09-04 | Pemetrexed | N | N | 310022924 | NIRAPARIB |
| 310008434 | 310010867 | 1.59 | 106 | Palliative (P) | 2018-04-15 | 2018-04-15 | TOPOTECAN | 01 | N | 310022967 | METHOTREXATE |
| 310008435 | 310005609 | 1.79 | 59.2 | Disease modification (D) | 2014-02-16 | 2015-06-26 | ICE | 02 | N | 310023019 | PEG INTERFERON |
| 310008436 | 310005610 | null | null | Palliative (P) | 2019-04-23 | 2019-05-29 | ICON8 TRIAL | N | N | 310023035 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 310008437 | 310005611 | 0 | 63.8 | Curative (C) | 2018-03-16 | 2018-03-16 | Oxaliplatin + Modified de Gramont | 02 | N | 310023035 | DOXORUBICIN + OLARATUMAB |
| 310008438 | 310005612 | 1.67 | null | Palliative (P) | 2015-07-24 | 2015-07-25 | ICON8 TRIAL | Y | N | 310023055 | EC |
| 310008439 | 310005613 | 0 | 80.7 | Curative (C) | 2017-05-19 | 2017-06-16 | DABRAFENIB + TRAMETINIB | 2 | N | 310023141 | EURO-EWING |
| 310008440 | 310005614 | 1.84 | 92.7 | Palliative (P) | 2016-10-03 | 2017-02-26 | Vemurafenib | N | N | 310023219 | IFOSFAMIDE |
| 310008441 | 310005614 | 1.75 | 80.4 | Adjuvant (A) | 2017-08-23 | 2017-09-06 | BCG Intravesical | 2 | N | 310023219 | CAPECITABINE + OXALIPLATIN |
| 310008442 | 310005614 | 0.6 | 67 | Neo-adjuvant (N) | null | 2016-11-22 | Bevacizumab+Carbo+Gemcitabine | N | N | 310023219 | BEVACIZUMAB + CARBO |
| 310008443 | 310005614 | 1.6 | null | Curative (C) | 2014-02-18 | 2014-02-18 | PMitCEBO | 02 | N | 310023219 | CETUXIMAB |
| 310008444 | 310005614 | null | 64.5 | Palliative (P) | 2017-12-16 | 2017-12-16 | Trabectedin | N | N | 310023219 | RUXOLITINIB |
| 310008445 | 310011936 | 1.67 | 98.41 | Curative (C) | 2017-04-01 | 2017-07-18 | Fluorouracil + Folinic + RT Bossett | 2 | null | 310023406 | CERITINIB |
| 310008446 | 310005615 | null | 95.8 | Palliative (P) | 2015-10-05 | 2015-11-01 | BEAM + Alemtuzumab Allo SCT | 2 | N | 310023408 | ALEMTUZUMAB |
| 310008447 | 310010034 | 1.65 | 62.6 | Adjuvant (A) | 2014-03-24 | 2014-03-26 | TOPOTECAN | 2 | N | 310023408 | TOPOTECAN |
| 310008448 | 310010034 | 1.78 | 0 | Palliative (P) | 2016-01-05 | 2016-01-05 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | N | 310023408 | ECX |
| 310008449 | 310005617 | null | null | null | 2017-01-12 | 2017-01-13 | Cytarabine intrathecal | 02 | null | 310023501 | DACARBAZINE |
| 310008450 | 310005617 | 1.8 | 20.2 | Disease modification (D) | 2018-01-17 | 2018-01-17 | EPOCH | N | N | 310023501 | ICE |
| 310008451 | 310005618 | 1.55 | 0 | Curative (C) | 2013-06-25 | 2013-06-27 | Bendamustine +/- Prednisolone | 02 | N | 310023588 | METHOTREXATE HIGH DOSE |
| 310008452 | 310005619 | 1.83 | 91.5 | Curative (C) | 2016-03-30 | 2016-05-03 | Topotecan (oral) | N | N | 310023611 | GEMCITABINE + OXALIPLATIN |
| 310008453 | 310005620 | 1.82 | 62.4 | Palliative (P) | 2017-03-03 | 2017-03-03 | ICE | N | N | 310023655 | TEMOZOLOMIDE |
| 310008454 | 310005625 | 1.68 | 85.3 | Palliative (P) | null | 2016-03-19 | VINCRISTINE | N | N | 310023689 | R IVAC |
| 310008455 | 310005626 | 1.66 | 68 | Palliative (P) | 2014-12-06 | 2015-03-30 | RCEOP | 02 | N | 310023699 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 310008456 | 310010035 | 1.62 | 58.7 | Palliative (P) | 2018-08-24 | 2018-08-26 | Irinotecan + Modified De Gramont | 02 | N | 310023712 | PEG INTERFERON |
| 310008457 | 310005627 | 1.68 | 71 | Palliative (P) | 2015-11-20 | 2015-11-26 | CISPLATIN + FLUOROURACIL | 2 | N | 310023716 | TRASTUZUMAB EMTANSINE |
| 310008458 | 310005628 | 1.67 | 155 | Not known (9) | 2013-09-30 | 2013-10-10 | DOXORUBICIN | N | N | 310023716 | IMATINIB |
| 310008459 | 310005629 | 1.65 | 59.1 | Adjuvant (A) | 2016-10-19 | 2016-11-13 | CVP R | N | N | 310023810 | CISPLATIN + FLUOROURACIL |
| 310008460 | 310005629 | 1.75 | 68.4 | Palliative (P) | 2016-10-14 | 2016-10-24 | Methotrexate High Dose (3g/m2) | N | N | 310023810 | PEG INTERFERON |
| 310008461 | 310005629 | 1.26 | null | Palliative (P) | 2015-07-12 | 2017-03-30 | METHOTREXATE | 2 | null | 310023810 | CETUXIMAB |
| 310008462 | 310005630 | 1.76 | 83.3 | Palliative (P) | 2017-02-14 | 2017-03-04 | CMV | 02 | N | 310023918 | CARBOPLATIN + ETOPOSIDE + THIOTEPA |
| 310008463 | 310005631 | 1.63 | 65 | Curative (C) | 2016-01-22 | 2016-02-11 | PEG INTERFERON | 02 | N | 310023973 | RUXOLITINIB |
| 310008464 | 310005631 | null | null | Disease modification (D) | 2017-01-16 | 2017-05-03 | Chlorambucil | N | Y | 310023973 | ICE-R |
| 310008465 | 310010037 | 1.73 | 101.7 | Palliative (P) | 2015-08-21 | 2015-08-27 | STS Rhabdomyosarcoma RMS 2005 IVA | null | null | 310024045 | ECX |
| 310008466 | 310010037 | null | 83.3 | null | 2017-03-28 | 2017-09-05 | PEG INTERFERON | 2 | N | 310024045 | METHOTREXATE HIGH DOSE |
| 310008467 | 310010037 | 1.78 | 64.3 | Curative (C) | 2016-07-03 | 2016-07-03 | INCA TRIAL | N | N | 310024045 | NIVOLUMAB |
| 310008468 | 310005632 | 1.76 | 104.3 | Palliative (P) | 2018-09-09 | 2018-10-09 | Temozolomide 200mg/m2 | Y | N | 310024116 | NIVOLUMAB |
| 310008469 | 310005634 | 1.59 | 80.1 | Curative (C) | 2015-09-21 | 2015-09-30 | MVAC | N | null | 310024207 | CYCLO + DOXORUBICIN + VINCRISTINE |